The ₹180 Crore Mystery: Chambal's PAT Credibility Takes a Hit
Management claimed Q1 PAT of ₹703 crore on the earnings call; the filed result shows ₹523.6 crore—a 34% gap with no public explanation. Combined with TAN utilization tracking 4% of first-year guidance, the quarter raises serious questions about forecasting discipline.
₹703 Cr
14% margin
₹523.6 Cr
10.4% margin
₹179.4 Cr
–34% discrepancy
The PAT question that went unanswered
In the opening remarks, MD Abhay Baijal stated: "Profit after tax grew 10% to ₹703 crores, with PAT margins at around 14%." The filed result shows ₹523.6 crore PAT with a 10.4% margin. That's a ₹180 crore (34%) gap. No analyst on the call picked it up. No management response. No explanation of consolidation basis, extraordinary items, or tax treatment. The discrepancy sits unresolved—a credibility red flag before we've closed the quarter.
The gap is too large to be rounding error or standalone-vs.-consolidated accounting. Without clarity on whether the ₹703 Cr includes subsidiary earnings, fair-value gains, or other non-recurring items, investors are left guessing at organic profitability. That opacity matters when guidance is the lynchpin of a multi-year thesis.
What management claimed, and what holds up
PAT grew 10% to ₹703 Cr with 14% margin
EBITDA margins expanded 350 bps to 17%
TAN progressing well, 75-80% first-year utilization target
Complex fertilizer EBIT jumped 67% through timely inventory purchase
NUP 2026 approved; fourth urea plant ready to bid in October
The EBITDA expansion and complex fertilizer EBIT jump are real—and the inventory purchase was well-timed, hedging subsidy delays and positioning the company ahead of Kharif demand. But the PAT discrepancy shatters credibility on the headline number. And the TAN miss is material: management guided 75–80% utilization in the first year; Q1 actual is approximately 4% of the 1.27 million-ton capacity (3.29 lakh tons booked, max run rate 9.5–10K tons per quarter). At this pace, the facility won't reach rated capacity for years, not one.
What changed on this call
TAN utilization
~4% (3.29L tons Q1)
Major downgrade; ramp now market-dependent
75–80% in first year
Fourth urea plant
Financial bids mid-Oct; Board approval TBD; commissioning 2030
Timeline extended, commitment pushed 4+ years
Imminent capex decision
Complex fertilizer margins
Will decline as inventory gains fade
One-time Q1 uplift; margin compression ahead
Benefiting from scale
Subsidy environment
Kharif +10% but Rabi yet to be announced; delay pressuring NPK
Demand risk if Rabi subsidy further delayed
Normal seasonal cycle
The bull-bear ledger
Diversified fertilizer portfolio and dealer network intact
EBITDA margin improvement (17%) shows operational leverage
Complex fertilizer inventory hedged subsidy delay risk well
Reported PAT credibility damaged by ₹180 Cr unexplained gap
TAN ramp 94% below guidance; no path to prior 75–80% target visible
Complex margins peak this quarter; compression expected next
Fourth urea plant still waiting for Board decision; ROE dilutive under NUP 2026
How the street is reading it
The stock fell 1.56% on day 1 post-result, then recovered to +2.9% by day 5—a modest bounce that reflects cautious repricing rather than conviction. The stock is now trading below its 20-, 50-, and 200-day moving averages (₹444.91, ₹459.18, ₹452.32 respectively), sitting 11% below its all-time high. That drawdown signals investors are repricing execution risk, but the tepid recovery suggests they haven't fully priced in either a recovery catalyst or a structural deterioration.
More telling: FII holdings trimmed to 14.92% from 15.11% last quarter, a small but material shift. DII remain flat at 5.34%. Promoters hold steady at 61.34%. The FII exit, though modest in basis points, signals that foreign money is not convinced the long-term story (NUP 2026, scale benefits) outweighs near-term headwinds (subsidy delays, TAN miss). A credible, well-explained earnings call would have arrested that flow; the unresolved PAT discrepancy likely accelerated it.
Ranked risks—what matters most to a holder
1
HighPAT reporting discrepancy (₹180 Cr gap)
If organic PAT is ₹523.6 Cr, not ₹703 Cr, earnings power is 26% lower than claimed. Management opacity erodes trust in forward guidance and makes valuation assumptions unreliable.
2
HighTAN utilization tracking 4% vs 75–80% guided
A high-capex asset running at 4% utilization drags ROI and ties up capital. If ramp accelerates only in Q3+, the facility won't reach target for years. Market demand risk is structural, not cyclical.
3
HighSubsidy delays pressuring NPK demand and margins
Rabi subsidy not yet announced. If delayed further or capped below cost inflation, NPK production (₹1,737 Cr Q1 revenue, 16.9% EBIT margin) faces demand destruction and sharp margin squeeze.
4
MediumComplex fertilizer margin compression (inventory gains fading)
Q1 CFZ EBIT ₹239 Cr (13.7% margin) is an artificial peak from advance inventory purchased at lower prices. As price averaging occurs, Q2+ margins will compress. Management guides 'margins will decline' but doesn't quantify.
5
MediumFourth urea plant capex still Board-pending; ROE dilutive under NUP 2026
₹10,000 Cr capex is not committed; Board approval required; timeline is 2030 (vague, 4+ years). ROE under new policy (12–16% range) is lower than prior. Execution risk high, returns dilutive.
6
MediumMonsoon & sowing variability (delayed onset impacted Q1)
Kharif sowing was 23% lower YoY as of end-June (though monsoon recovered in July). Another dry spell would dampen demand across urea, DAP, NPK segments. Seasonal, but acute if it occurs.
The debate
What to watch next
1 · Q2 earnings (demand recovery & margin trajectory)
Monsoon recovered in July; farmer urea sales hit 3.8 lakh tons in July alone (vs. lower June levels). If Q2 revenue and volume rebound sharply, it validates guidance that 'H2 will exceed H1.' The critical number: complex fertilizer EBIT. If it stays elevated (>₹230 Cr), inventory gains haven't fully faded and margins are holding. If it drops below ₹150 Cr, compression is acute and Q3 headwind is worse.
2 · October financial bids & Board decision on fourth urea plant
If Board approves capex and bids come in below ₹10,000 Cr estimate, ROE improves and the project becomes tangible. If bids exceed guidance or Board delays further, capex doubt lingers and fourth plant becomes a 2025–2026 story, not near-term. Watch for vendor allocation (first-mover advantage) and execution timeline clarity.
3 · Rabi subsidy announcement & TAN HDAN commissioning (Q3+ ramp)
If Rabi subsidy is announced at higher rates to offset geopolitical inflation, NPK demand accelerates and complex fertilizer margins stabilize or improve. If delayed further, NPK production stays low and margins stay compressed through Q3. Simultaneously, if TAN HDAN begins commercial production in Q3 with utilization >15–20% of capacity (vs. 4% now), the facility is on the ramp path. Sub-10% utilization by Q3 signals deeper market weakness and execution issues.
The single number to track
Organic PAT (adjusted for consolidation, tax, and one-time items). Until the ₹180 Cr gap is resolved, every quarter's headline profit will carry credibility risk. If Q2 earnings clearly disclose standalone vs. consolidated PAT, extraordinary items, and tax provisions, confidence returns. If the company avoids disclosure again or the gap widens, assumption of ongoing accounting opacity is justified—and multiple compression will follow. The organic number, cleanly disclosed, is the restart button for this stock.
Q1 FY27 is a steady-hand quarter for CFCL operationally, but a credibility step backward. Revenue decline and subsidy delays are cyclical headwinds; TAN underutilization and the ₹180 Cr PAT discrepancy are execution and transparency issues. The long-term urea story (NUP 2026, fourth plant, scale benefits) remains intact, but near-term margin compression is now consensus risk and management credibility has taken a hit. Hold here, pending Q2 organic profit clarity and October capex news. If PAT is transparently reconciled and TAN ramp accelerates visibly (>10% utilization by Q3), the beaten-down valuation (11% below ATH, trading below key moving averages) offers a multi-year entry into capex commissioning and scale benefits. Until then, this is a show-me story, not a conviction hold.
Weak Q1, long-term optionality hinges on government policy
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
Stood by prior FY26 guidance on overall FY27 volumes; TAN first-year utilization is tracking 4% vs 75-80% guided—major miss. Subsidy delay and monsoon disruption are external, but margin benefit is one-time.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 FY27 revenues declined 11.8% YoY on weak Kharif sowing (delayed monsoon, plant shutdowns) and raw material price spikes. Reported PAT of ₹523.6 Cr is significantly below management's stated ₹703 Cr (34% gap, unexplained). Margins are inflated by prior inventory purchases; compression expected as averaging occurs and subsidy delays persist. Long-term growth story (NUP 2026, TAN project, fourth urea plant) is intact but dependent on government policies and Board approvals still pending, with TAN ramping well below prior 75-80% first-year guidance.
₹5027 Cr
Revenue · −11.8% YoY₹523.6 Cr
Reported PAT · −4.6% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
PAT grew 10% to ₹703 Cr with 14% PAT margin
MISSDelivered PAT is ₹523.6 Cr (10.4% margin), not ₹703 Cr; 34% discrepancy unexplained
EBITDA margins expanded 350 bps to 17%
METOPM/EBITDA margin is 16.9% vs prior 13%, confirmed, though prior quarter comparison in transcript differs from YoY basis
TAN progressing well with production commenced, high-density moves closer to commissioning
OVERSTATEDWNA and ANS in trial; G3 HDAN utilization is ~4% of 1.27M ton capacity (vs prior 75-80% first-year guidance); Q1 volumes 3.29L tons G3 only
Complex fertilizer EBIT rose 67% through timely inventory purchase
METConfirmed; but margin decline expected as inventory gains reverse and price averaging occurs
8.5 lakh tons of NPK vendor tieups secure seasonal supply
METConfirmed in Q&A; procurement well-timed to hedge subsidy delay
NUP 2026 approval provides strong framework for fourth urea plant at ~₹10,000 Cr capex
MixedPolicy approved; company still in preparatory phase, financial bids expected mid-October, no Board approval yet, no capex commitment
Earnings quality
What changed since the last call
TAN utilization trajectory reset lower
DowngradePrior Q4 FY26 call guided 75-80% first-year TAN utilization; Q1 FY27 actual is ~4% (3.29L tons G3 vs 1.27M ton capacity). Run rate 9.5-10K tons/qtr, nowhere near guidance. Ramp now tied to market recovery.
Fourth urea plant timeline extended
NeutralNUP 2026 approved in Q1, but financial bids not due until October, Board approval still pending, commissioning moved to 'within 2030' (vague, 4+ years). No acceleration visible despite policy support.
Complex fertilizer margins expected to compress
DowngradeSegment EBIT up 67% to ₹239 Cr this quarter due to advance inventory purchase at ₹2,131 Cr revenue. Management now guides 'margins will decline as averaging of prices happen.' Signals Q2+ margin headwind.
Subsidy delay pressuring NPK profitability
DowngradeKharif subsidy announced ~10% higher but before geopolitical price spike; not yet revised upward. Industry pressed on interim relief; none granted. Chambal's early procurement hedges but sector margins under stress through Rabi.
The Q&A
Analysts pressed hard on TAN utilization gap (75-80% vs 4% actual), subsidy timing (delayed Rabi announcement), fourth urea plant allocation process (capex risk if vendors book early), and Reliance threat to TAN margins. Management held firm on TAN ramp timing (Q3+), blamed external delays on subsidy/vendor availability, and emphasized brownfield scale/execution track record for urea capex. Tone was prepared and defensive, not bullish.
Fourth urea plant eligibility & capex — Prashant, Elara Capital
AnsweredSlight mixture of both. Will formally approach, process includes bank guarantees after government approval. Strong contender. Financial bids expected mid-October, Board approval prerequisite. Application window already open.
TAN revenue & G3 capacity split — Prashant, Elara Capital
AnsweredNot shown in segments—not booked yet in P&L, decapitalized as project cost. G1 96K tons, G2 1.85L tons, G3 3.29L tons. Maximum run rate 9.5–10K tons/qtr; cannot complete 1.27M tons before policy period ends.
Complex fertilizer margin sustainability — Shivam Gupta, Trinetra Asset Managers
AnsweredYes, advance NPK purchases from previous quarter helped placement and margins. Margins will decline as price averaging happens, but will maintain a certain level. Have tied up 8.5L tons with vendors.
NUP 2026 vs NIP 2012 ROE comparison — Viraj Kacharia, SiMPL
PartialDilutive agreed, but scale benefits at single site (four plants together = largest in India, 2nd in Asia after Qatar QAFCO) offset it. Fixed costs, manpower, dealer cross-sell benefits large. Expected EBITDA ~₹12,000/ton steady-state (dollar conversion at ~₹13,500/USD today). Gains not capped if efficiencies driven.
Subsidy delay impact on NPK — Dhruv Muchhal, HDFC AMC
AnsweredGovernment watching stock levels, El Nino progress, Rabi readiness. Balancing act with fiscal situation. Urea and DAP costs fully absorbed, others supplementary. Possible interim relief sought but not yet granted. Expected action by October for Rabi.
TAN market supply/demand risk — Mayuresh, invest4Edu
PartialCapacity and demand both rising. Infrastructure stress (roads, ports, blasting for coal/mining) is bullish. Will be short-to-slightly long ~1 year, then short again. Pricing structure and cost mix matter. Reliance entry hypothetical; can't speculate timeline. No roadblocks today.
Gas price & net cash position — Prashant, Elara Capital
AnsweredGas price Q1 was USD 17.25/NCV basis (provisional). Net borrowing ₹200 Cr (negative cash).
Q2 demand outlook & monsoon recovery — Sanjay K, individual investor
AnsweredYes, monsoon strengthened in July. Farmer urea sales 3.8L tons in July alone, NPK 92–93K tons. Pickup ~19–20K tons/day, quite good. Q2 expected to progress well; channel liquidation will create second round of demand.
Urea margin drivers (ammonia, currency) — Dhruv Muchhal, HDFC AMC
AnsweredThree factors: Gadepan-3 predominance this quarter (higher-margin plant), currency uptick (direct margin impact for G3), surplus ammonia sales at better margins.
Capital allocation: dividends vs buyback — Karan Gupta, CAVI Capital
AnsweredDividend: will maintain current levels (25% payout policy). Buyback: subject to lack of project visibility; if no major projects, will step in. Not on horizon now given capex pipeline.
Guidance
FY27 urea volumes expected to exceed FY26 (per prior FY26 calls)
MediumQ1 FY27 volumes impacted by plant shutdown bunching; expected recovery in H2 as Kharif and Rabi seasons progress. Monsoon improvement in July signals better demand.
Complex fertilizer margins to decline from Q1 peak as inventory gains fade
HighQ1 EBIT ₹239 Cr (13.7% margin) benefited from advance NPK purchase at lower prices. Price averaging will compress margins next quarter as subsidies remain delayed.
TAN EBITDA ~₹12,000/ton expected at steady state under NUP 2026
LowAssumes project cost optimization (₹9,000–10,000 Cr capex), dollar conversion at ~₹13,500/USD, efficiency gains not capped by policy. Highly dependent on capex execution and subsidy structure finalization.
Fourth urea plant capex ~₹10,000 Cr; financial bids expected mid-October, commissioning by 2030
LowStill in preparatory phase; Board approval not yet sought. Timing and amount subject to policy confirmation, vendor availability, and cost optimization. No capex commitment visible.
Risks the call surfaced
Subsidy & government policy
HighKharif subsidy rates revised only +10%, announced before geopolitical price spike. Interim relief sought but not granted. Rabi subsidy not yet declared. Risk of demand destruction if subsidy remains below cost inflation.
TAN utilization shortfall
HighTAN plant guided at 75–80% first-year utilization; Q1 actual is ~4% of 1.27M ton capacity. Ramp-up dependent on market demand recovery (mining, infrastructure, blasting). If demand doesn't materialize, high capex asset will drag ROI.
PAT reporting discrepancy
HighTranscript claims standalone PAT ₹703 Cr; delivered filed result shows ₹523.6 Cr—34% gap. Cause (consolidation, extraordinary items, one-time gains) not explained on call. Suggests either accounting opacity or extraordinary gains in claimed figure.
Complex fertilizer margin sustainability
MediumQ1 complex fertilizer EBIT jumped 67% to ₹239 Cr driven by advance inventory purchase at lower prices (non-recurring benefit). Management guides margins to decline as price averaging occurs and inventory cost basis rises. Risk of sharp Q2 margin contraction.
Fourth urea plant capex uncertainty
MediumFourth urea plant (~₹10,000 Cr capex) still in early preparatory phase. Financial bids not due until mid-October; Board approval required before commitment. ROE under NUP 2026 (12–16% floor-ceiling) is dilutive vs NIP 2012. Capex overrun, vendor delays, or policy changes could derail project economics.
Monsoon & sowing variability
MediumQ1 FY27 saw delayed monsoon onset, below-normal rainfall, and delayed Kharif sowing (~23% lower YoY as of end-June). While monsoon recovered in July, sustained dry spell or crop failure could dampen demand.
Management
Score 6/10. Clear and detailed on operational metrics; guards against speculation on hypothetical scenarios ('I don't think there is a cap per se'). Transparent on external headwinds (subsidy delays, monsoon disruption). Vague on capex commitment and PAT discrepancy. Track record solid on plant construction (Gadepan-3 delivered on time, now TAN trial phase). TAN ramp-up materially below 75–80% first-year guidance (now 4% utilization). Inventory procurement well-timed, hedging subsidy delay.
1 · Oct 2026
Financial bids for fourth urea plant (~₹10,000 Cr capex); Board decision follows
2 · Q2 FY27
Monsoon ramp-up, accelerated Kharif sowing catch-up, higher urea/NPK offtake
3 · Q3 FY27 onwards
TAN HDAN commissioning, three-product lineup (WNA, Nitrate Melt, HDAN); utilization ramp expected
Long-term growth story (NUP 2026, TAN project, fourth urea plant) is intact but dependent on government policies and Board approvals still pending, with TAN ramping well below prior 75-80% first-year guidance.
Chambal Q1: JV loss drags consolidated PAT to ₹524 Cr (-5% YoY); core up ~7%, margins expand
PAT -4.61% YoY · revenue -11.77% · margins expanding
₹5,027.02 Cr
-11.77% YoY
₹523.6 Cr
-4.61% YoY
10.36%
+0.8pp YoY
₹13.07
Consolidated net profit for Q1 FY27 came in at ₹523.6 Cr, down 4.6% from ₹548.9 Cr a year earlier, on revenue of ₹5,027 Cr that fell 11.8% YoY. The headline decline is misleading: it is entirely attributable to the Moroccan phosphate joint venture (IMACID), whose equity-accounted share swung to a ₹25.1 Cr loss this quarter from a ₹36.1 Cr profit a year ago — a ~₹61 Cr YoY drag. Strip the JV out and consolidated PAT actually rose ~7% YoY. The sequential surge (PAT up 209% from ₹169 Cr in Q4) is a seasonality artifact — Q1 captures the kharif fertiliser season against a structurally weak Q4 — and should not be read as a step-change.
Q1 FY-2027 vs prior quarters
Beneath the topline dip, the core business strengthened. Net margin expanded to 10.4% from 9.6% a year ago, and segment profit before finance costs and tax rose 11% YoY to ₹778.9 Cr even as every segment's revenue fell. Complex Fertilisers was the standout — profit up 67% to ₹238.7 Cr on revenue down 18% — while Crop Protection profit rose 13% to ₹108.4 Cr, both signs of pricing/mix discipline over volume. Standalone tells a cleaner version of the same story: PAT of ₹703.5 Cr, up 10.3% YoY, with PBT up 10% to ₹926.6 Cr; the >15-point gap between standalone (+10%) and consolidated (-5%) growth is the JV, which only enters the group numbers. Finance costs jumped to ₹16.8 Cr from ₹2.4 Cr, reflecting borrowings for the Technical Ammonium Nitrate (TAN) plant and brownfield capex now moving through the P&L.
The stock went into the print at ₹443, down 6.2% over the past month of trading.
Management guides for significant contribution from the newly commissioning Technical Ammonium Nitrate (TAN) plant, targeting 75-80% utilization in its first year within a buoyant market. While near-term urea volumes will be impacted by a plant shutdown, overall FY27 volumes are expected to exceed FY26. The company is
— This quarter: met
On the last (Q4 FY26) call management flagged that near-term urea volumes would be dented by a plant shutdown while FY27 volumes should still exceed FY26, and pointed to the new TAN plant (targeting 75-80% utilisation) plus high-margin Crop Protection as growth engines. Q1 is consistent with that framing: Own Manufactured Fertilisers (largely urea) revenue fell 8% YoY, while the TAN-housing 'Others' segment is still negligible (₹0.05 Cr result) as it commissions — the FY27 volume-beat and TAN ramp remain to be proven in coming quarters. No published Street consensus for Q1 FY27 was available at the time of writing (no brokerage preview surfaced). The board separately set August 11, 2026 as the dividend record date; results carry an unmodified limited-review conclusion. The company gives no formal quarterly guidance beyond the qualitative FY27 outlook above.
W1
TAN plant ramp: 'Others' segment result still negligible at ₹0.05 Cr; management targets 75-80% utilisation in FY27 — watch for first meaningful contribution.
W2
Urea volumes: Own Manufactured Fertilisers revenue down 8% YoY on plant shutdown; management guides FY27 total volumes to exceed FY26.
W3
IMACID JV: needs to turn back from the ₹25.1 Cr loss; it swung consolidated PAT by ~₹61 Cr YoY this quarter.
Clean digital PDF, unaudited/limited review. Consolidated PBT is after equity-method share of JV NET LOSS of ₹25.10 Cr (IMACID) vs +₹36.12 Cr year-ago — the swing drives the YoY consolidated PAT dip. Standalone PAT printed as '103.49' is an OCR/typo for 703.49 (926.59 PBT − 223.10 tax = 703.49). NCI negligible (owners' share ₹523.61 Cr).